Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | SGK1 | O00141 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176904 | 1.00 | SLC6A4 (0.54) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3184197 | 1.00 | SLC6A4 (0.54) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3182867 | 0.93 | SLC6A4 (0.57) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3191094 | 0.93 | SLC6A4 (0.57) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3182879 | 0.93 | SLC6A4 (0.57) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3162908 | 0.79 | SLC6A4 (0.59) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| Hydrochloric Acid SCHEMBL4510800 | 0.76 | SLC6A4 (0.58) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| Hydrochloric Acid SCHEMBL3327587 | 0.75 | SLC6A4 (0.49) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL3175037 | 0.75 | SLC6A4 (0.70) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B | |
| SCHEMBL15062036 | 0.74 | SLC6A4 (0.77) | SLC6A4SLC6A2HTR2ASLC6A3HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | claimed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659394-B2 | Substituted morpholine compounds for the treatment of central nervous system disorders | PFIZER INC (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1745029-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | SLC6A4 235/4885SLC6A2 124/4885HTR2A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.